InflaRx NV IFRX:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
2.64quote price arrow up+0.04 (+1.54%)
Volume
99,807
52 week range
0.78 - 5.69
Loading...
  • Open2.60
  • Day High2.70
  • Day Low2.51
  • Prev Close2.60
  • 52 Week High5.69
  • 52 Week High Date11/15/21
  • 52 Week Low0.78
  • 52 Week Low Date06/24/22

Key Stats

  • Market Cap116.69M
  • Shares Out44.20M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-44.54

KEY STATS

  • Open2.60
  • Day High2.70
  • Day Low2.51
  • Prev Close2.60
  • 52 Week High5.69
  • 52 Week High Date11/15/21
  • 52 Week Low0.78
  • 52 Week Low Date06/24/22
  • Market Cap116.69M
  • Shares Out44.20M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-44.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.91
  • P/E (TTM)-2.91
  • Fwd P/E (NTM)-2.22
  • EBITDA (TTM)-40.277M
  • ROE (TTM)-33.90%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)1.55%

EVENTS

  • Earnings Date11/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On InflaRx NV

 

Profile

MORE
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial...
Nicolas Fulpius
Independent Chairman of the Board
Niels Riedemann
Chief Executive Officer, Executive Director
Thomas Taapken
Chief Financial Officer
Address
Winzerlaer Str. 2
Jena
07745
Germany

Top Peers

SYMBOLLASTCHG%CHG
ADVM
Adverum Biotechnologies Inc
0.95+0.0013+0.14%
RZLT
Rezolute Inc
2.74+0.03+1.11%
DBTX
Decibel Therapeutics Inc
3.46+0.06+1.76%
CADL
Candel Therapeutics Inc
3.14-0.06-1.88%
GALT
Galectin Therapeutics Inc
1.63-0.02-1.21%